These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38161143)

  • 21. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
    Yang W; Lu YP; Yang YZ; Kang JR; Jin YD; Wang HW
    J Obstet Gynaecol Res; 2017 Oct; 43(10):1602-1612. PubMed ID: 28833798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Programmed Death-Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma.
    Hongo T; Kuga R; Miyazaki M; Komune N; Nakano T; Yamamoto H; Koike K; Sato K; Kogo R; Nabeshima K; Oda Y; Nakagawa T
    Laryngoscope; 2021 Dec; 131(12):2674-2683. PubMed ID: 34143491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva.
    Czogalla B; Pham D; Trillsch F; Rottmann M; Gallwas J; Burges A; Mahner S; Kirchner T; Jeschke U; Mayr D; Schmoeckel E
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):569-577. PubMed ID: 32025868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma.
    Chen X; Chen H; Lin R; Li Y; Guo Y; Chen Q; Zhang Y; Cai G; Hu M; Chen G
    J Clin Pathol; 2023 Dec; 77(1):61-67. PubMed ID: 36319076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.
    Nagarajan P; El-Hadad C; Gruschkus SK; Ning J; Hudgens CW; Sagiv O; Gross N; Tetzlaff MT; Esmaeli B
    Invest Ophthalmol Vis Sci; 2019 May; 60(6):2388-2398. PubMed ID: 31141610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment.
    Sato F; Ono T; Kawahara A; Kawaguchi T; Tanaka H; Shimamatsu K; Kakuma T; Akiba J; Umeno H; Yano H
    J Clin Pathol; 2019 Aug; 72(8):542-549. PubMed ID: 31113825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study.
    Necchi A; Spiess PE; Bandini M; Basile G; Grivas P; Bratslavsky G; Jacob J; Danziger N; Lin D; Decker B; Sokol ES; Huang RSP; Kulkarni SB; Ross JS
    Oncologist; 2022 Dec; 27(12):1016-1024. PubMed ID: 35881043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
    Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
    Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
    Roper E; Lum T; Palme CE; Ashford B; Ch'ng S; Ranson M; Boyer M; Clark J; Gupta R
    Pathology; 2017 Aug; 49(5):499-505. PubMed ID: 28666643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
    Ghelani GH; Zerdan MB; Jacob J; Spiess PE; Li R; Necchi A; Grivas P; Kamat A; Danziger N; Lin D; Huang R; Decker B; Sokol ES; Cheng L; Pavlick D; Ross JS; Bratslavsky G; Basnet A
    Urol Oncol; 2023 Dec; 41(12):486.e15-486.e23. PubMed ID: 37821306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papillomavirus infection affects treatment outcomes and the immune microenvironment in patients with advanced penile squamous cell carcinoma receiving programmed cell death protein 1 inhibitor-based combination therapy.
    Wei L; Li Z; Guo S; Ma H; Shi Y; An X; Huang K; Xiong L; Xue T; Zhang Z; Yao K; Luo J; Han H
    Cancer; 2024 May; 130(9):1650-1662. PubMed ID: 38157276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma.
    Wuerdemann N; Gültekin SE; Pütz K; Wittekindt C; Huebbers CU; Sharma SJ; Eckel H; Schubotz AB; Gattenlöhner S; Büttner R; Speel EJ; Klussmann JP; Wagner S; Quaas A
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
    Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M
    Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
    Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
    Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
    Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
    Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
    Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
    Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.